Table 4 Univariate analysis of baseline characteristics to determine associations with disease severity in patients with multiple sclerosis.
| Ā | EDSS scoreāā„ā4.0 (Nā=ā16) | EDSS scoreā<ā4.0 (Nā=ā40) | p value |
|---|---|---|---|
Age, years | 56ā±ā11.2 | 43.3ā±ā12.3 | <ā0.001* |
Sex (female), n (%) | 12 (75) | 31 (77.5) | 0.841 |
Disease duration, years | 19.0ā±ā8.8 | 11.2ā±ā8.7 | 0.004* |
Current smoking, n (%) | 2 (12.5) | 3 (7.7) | 0.573 |
Current dental visiting, n (%) | 9 (56.3) | 12 (30.8) | 0.077 |
High relative abundance of F. nucleatum, n (%) | 8 (50.0) | 5 (12.5) | 0.003* |
MS subtype | Ā | Ā | <ā0.001* |
RRMS, n (%) | 8 (50.0) | 38 (95.0) | Ā |
SPMS, n (%) | 8 (50.0) | 2 (5.0) | Ā |
Number of attacks | 4.2ā±ā4.8 | 2.2ā±ā2.6 | 0.046 |
Relapse within one year, n (%) | 3 (18.8) | 5 (12.5) | 0.546 |
MRI findings | |||
Periventricular, n (%) | 16 (33.3) | 32 (80.0) | 0.053 |
Cortical or juxtacortical, n (%) | 11 (68.8) | 30 (75.0) | 0.633 |
Infratentorial, n (%) | 13 (81.3) | 28 (70.0) | 0.390 |
Spinal cord, n (%) | 13 (81.3) | 29 (72.5) | 0.495 |
DMD | Ā | Ā | 0.427 |
Low-efficacy treatment or drug free, n (%) | 7 (43.8) | 13 (32.5) | Ā |
High-efficacy treatment, n (%) | 9 (56.3) | 27 (67.5) | Ā |